Day One Biopharmaceuticals (DAWN) Operating Income: 2023-2025
Historic Operating Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$24.3 million.
- Day One Biopharmaceuticals' Operating Income fell 181.83% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.6 million, marking a year-over-year increase of 21.67%. This contributed to the annual value of -$217.3 million for FY2024, which is 5.44% down from last year.
- According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Operating Income is -$24.3 million, which was up 30.66% from -$35.0 million recorded in Q2 2025.
- Day One Biopharmaceuticals' Operating Income's 5-year high stood at $29.6 million during Q3 2024, with a 5-year trough of -$114.8 million in Q2 2024.
- Moreover, its 3-year median value for Operating Income was -$48.6 million (2023), whereas its average is -$47.4 million.
- In the last 5 years, Day One Biopharmaceuticals' Operating Income skyrocketed by 157.61% in 2024 and then slumped by 181.83% in 2025.
- Over the past 3 years, Day One Biopharmaceuticals' Operating Income (Quarterly) stood at -$59.5 million in 2023, then declined by 9.77% to -$65.3 million in 2024, then crashed by 181.83% to -$24.3 million in 2025.
- Its last three reported values are -$24.3 million in Q3 2025, -$35.0 million for Q2 2025, and -$41.1 million during Q1 2025.